DRAFT AGENDA

BLOOD PRODUCTS ADVISORY COMMITTEE
65th Meeting - March 16-17, 2000
Holiday Inn, Silver Spring
8777 Georgia Avenue, Silver Spring, MD

Thursday, March 16, 2000

8:00 a.m. Statement of Conflict of Interest

8:05 a.m. Welcome and Opening Remarks

8:10 a.m. Committee Updates

- Summaries of Recent Workshops:
 - 1. Bacterial Contamination of Platelets Chiang Syin, Ph.D.
 - Criteria for Safety and Efficacy Evaluation of Oxygen Therapeutics as Red Cell Substitutes - Paul Aebersold, Ph.D.
 - 3. Implementation of Universal Leukoreduction Jong-Hoon Lee, M.D.
 - 4. NIH Workshop on Parvovirus B19 Thomas Lynch, Ph.D.

9:30 a.m. Open Committee Discussion

I. Indeterminate HIV-1 Western Blots With Only Non-viral Bands

- A. Introduction and Background Paul Mied, Ph.D., Deputy Director, Division of Emerging and Transfusion Transmitted Diseases, OBRR
- B. Data from Clinical Studies Christopher Bentsen, Genetic Systems Corp., Redland, WA
- C. ARC Experience with Indeterminate Blood Donors Stramer, Ph.D., American Red Cross, Rockville, MD
- D. Significance of HIV Indeterminates Western Blot Results - Michael Busch, M.D., Ph.D., Blood Centers of the Pacific, San Francisco, CA
- E. Risk of False Negatives Thomas L. Hearn, M.D. Centers for Disease Control and Prevention, Atlanta, GA

10:30 a.m. OPEN PUBLIC HEARING

(Statements from Bio-Rad, Calypte, Epitope) (Statements from AABB, ABC, APHL)

11:00 a.m. BREAK

11:30 a.m. Open Committee Discussion

- F. Questions for the Committee
- G. Committee Discussion and Recommendations

12:30 p.m. LUNCH

1:30 p.m. Open Committee Discussion

II. History of Hepatitis

- A. Introduction and Background Robin Biswas, M.D., Division of Emerging and Transfusion Transmitted Diseases
- B. Presentation Ian Williams, M.D., Hepatitis Branch, Centers for Diseases Control and Prevention
- C. Presentation Harvey Alter, M.D., Chief, Infectious Diseases, Department of Transfusion Medicine, NIH

2:30 p.m. OPEN PUBLIC HEARING

3:00 p.m. Open Committee Discussion

- D. Questions for the Committee
- E. Committee Discussion and Recommendations

3:30 p.m. III. HBV Nucleic Acid Testing

- A. Introduction and Background Edward Tabor, M.D.
- B. Presentation Kusuya Nishioka, M.D. Japanese Red Cross Blood Center
- C. Presentation Susan Stramer, Ph.D., American Red Cross
- D. Scientific Presentations Charles Watson, Ph.D., Centeon
- E. Scientific Presentation Andrew Conrad, Ph.D.,

- 4:30 p.m. OPEN PUBLIC HEARING
- 5:00 p.m. Open Committee Discussion
 - F. Committee Discussion and Recommendations
- 6:00 p.m. Recess (until 8:00 a.m. Friday, March 17, 2000)

Friday, March 17, 2000

- 8:00 a.m. Committee Updates
 - Summary of January 2000 PHS Advisory Committee Meeting on Blood Safety and Availability Stephen Nightingale, M.D.
 - CJD Policy Dorothy Scott, M.D.
 - HCV Lookback Guidance Paul Mied, Ph.D.
 - Post Donation Information Algorithm Edward Tabor,
 M.D.
 - IGIV Clinical Endpoints Basil Golding, M.D.
- 9:00 a.m. Open Committee Discussion
 - IV. Blood Action Plan: Supply Issues Informational
 - Mary Gustafson, Director, Division of Blood
 Applications
- 9:30 a.m. OPEN PUBLIC HEARING
- 10:00 a.m. BREAK
- 10:30 a.m. Open Committee Discussion
 - V. Donor Deferral Issues Related to Xenotransplantation
 - A. Introduction and Background Andrew Dayton, M.D., Ph.D., Laboratory of Molecular Virology, DETTD
 - B. Questions for the Committee

- 11:30 a.m. **PUBLIC HEARING**
- 12 Noon Open Committee Discussion
 - C. Committee Discussion and Recommendations
- 12:30 p.m. LUNCH
 - 1:30 p.m. VI. Report of Intramural Site Visit: Laboratory of Plasma Derivatives, Division of Hematology
 - A. Introduction and Overview
 - Neil Goldman, Ph.D., Associate Director for Research, CBER
 - John Finlayson, Ph.D., Associate Director for Science, OBRR
 - 3. Mark Weinstein Ph.D., Director, Division of Hematology
 - 4. Summary of Laboratory of Plasma Derivatives - Basil Golding, M.D., Chief, Laboratory of Plasma Derivatives, DH
- 3:00 p.m. CLOSED COMMITTEE DELIBERATIONS
- 3:30 p.m. ADJOURNMENT